HOME Press Releases Blood Glucose Monitoring System Market worth 10.58 Billion USD by 2022



Blood Glucose Monitoring System Market worth 10.58 Billion USD by 2022


The report "Blood Glucose Monitoring System Market by Product (Self-Monitoring, Continuous Glucose Monitoring Devices), Testing Site (Fingertip), Patient Care Setting (Hospital, Homecare), Application (Type 1, Type 2, Gestational Diabetes) - Global Forecast to 2022", The global blood glucose monitoring system market is projected to reach USD 10.58 Billion by 2022 from an estimated USD 8.35 Billion in 2017, at a CAGR of 4.8% during the forecast period. The key factors driving the growth of this market include rising prevalence of diabetic population, and increasing innovative product launches resulting in increased adoption amongst patients.

Browse 160 market data Tables and 46 Figures spread through 181 Pages and in-depth TOC on "Blood Glucose Monitoring System Market by Product (Self-Monitoring, Continuous Glucose Monitoring Devices), Testing Site (Fingertip), Patient Care Setting (Hospital, Homecare), Application (Type 1, Type 2, Gestational Diabetes) - Global Forecast to 2022"
https://www.marketsandmarkets.com/Market-Reports/blood-glucose-monitoring-system-market-14912252.html
Early buyers will receive 10% customization on reports.

By product, the self-monitoring blood glucose systems segment is expected to account for the largest share of the market in 2017

On the basis of product, the blood glucose monitoring system market is segmented into self-monitoring blood glucose systems and continuous glucose monitoring systems. In 2017, the self-monitoring blood glucose system segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to product enhancements resulting in improved accuracy and requirement of less blood sample, and their high adoption in emerging markets.

By testing site, the fingertip testing segment is expected to account for the largest share of the market in 2017

On the basis of testing site, the blood glucose monitoring system market is segmented into fingertip testing and alternate site testing. In 2017, the fingertip testing segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to accuracy and high reliability on fingertip testing.

By patient care setting, the self/home care segment is expected to account for the largest share of the market in 2017

On the basis of patient care setting, the blood glucose monitoring system market is segmented into self/home care and hospital & clinics. In 2017, self/home care segment is expected to account for the largest share of the global market. The large share of this segment can be primarily attributed to factors such as growing diabetic population, and increasing preference for less invasive technologies that can be used at home.

By application, the type 2 diabetes segment is estimated to dominate the market in 2017

Based on application, the market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. The type 2 diabetes segment is expected to command the largest share of the blood glucose monitoring system market in 2017. The large share of this segment can be attributed to increasing incidence of type 2 diabetes, and increasing product launches to enhance patient comfort.

North America to dominate the market in 2017

In 2017, North America is expected to account for the largest share of the blood glucose monitoring system market, followed by Europe. Factors such as a favorable reimbursements, awareness programs, rising FDA approvals in the US, and rising prevalence of diabetes in the US and Canada are contributing to the large share of North America.

The key players in the global blood glucose monitoring system market are Roche (Switzerland), Abbott (US), LifeScan (US), Ascensia (Switzerland), Medtronic (Ireland), Dexcom (US), Ypsomed (Switzerland), B. Braun (Germany), Nipro (Japan), Sanofi (France), ARKRAY (Japan), Prodigy Diabetes Care (US), ACON Laboratories (US), and Nova Biomedical (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

We will organize an analyst call and demonstrate the latent opportunities and threats which will likely impact your business, at no cost.

Speak to Analyst


* Name :
* Business Email :
* Phone :
* Designation :
* Country:
Report MD 5831: Blood Glucose Monitoring System Market by Product (Self-Monitoring, Continuous Glucose Monitoring Devices), Testing Site (Fingertip), Patient Care Setting (Hospital, Homecare), Application (Type 1, Type 2, Gestational Diabetes) - Global Forecast to 2022
* Enter the text from the image
   to the textbox :
7 6 8 6 8  
Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports